...
首页> 外文期刊>The oncologist >Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
【24h】

Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.

机译:金黄色葡萄球菌凝固酶阳性的皮肤炎症与表皮生长因子受体靶向治疗有关:乳头丘疹爆发的早期和晚期。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Cutaneous eruptions, mainly papulopustular, are the most common associated side effects of epidermal growth factor receptor inhibitors (EGFRIs). This study investigated the possible role of bacterial infection in EGFRI-induced eruptions and its relation to clinical morphology. PATIENTS AND METHODS: The study group consisted of all 29 patients referred for dermatologic evaluation of side effects of cetuximab or erlotinib from March 2008 to November 2009. Specimens were taken for bacterial culture from pustules in patients with grade >1 papulopustular rash and from periungual secretions in patients with paronychia. RESULTS: Twenty-four of 29 patients had a papulopustular reaction; five of 29 had paronychia/xerosis. Of the papulopustular eruption patients, time to rash appearance yielded two distinct groups: early-phase, median 8 days after drug initiation, located mainly on the face (n = 17) and late-phase, median approximately 200 days after drug initiation, located mainly on the trunk (n = 7). Bacterial culture grew Staphylococcus aureus (SA) in seven of 13 early-phase patients tested and in all late-phase patients. Treatment consisted of topical steroids with or without topical/systemic antibiotics. All patients had a clear improvement in their cutaneous symptoms within a few days. Dose reduction or temporary discontinuation of the EGFRI was necessary in only four of 29 patients. CONCLUSIONS: As described in the literature, EGFRI-induced papulopustular eruption may appear early and probably is an inflammatory process with or without SA secondary infection. The papulopustular eruption may also appear as a late phase, described here for the first time, which is an infectious process with all patients being SA(+). The >50% overall incidence of SA infection in our study highlights the need for routine bacterial cultures from EGFRI-induced eruption.
机译:目的:表皮生长因子受体抑制剂(EGFRIs)最常见的副作用是皮肤爆发,主要是乳头状脓疱。这项研究调查了细菌感染在EGFRI诱发的爆发中的可能作用及其与临床形态的关系。患者与方法:研究组由2008年3月至2009年11月接受皮肤科评估西妥昔单抗或厄洛替尼副作用的所有29例患者组成。对标本≥1的丘疹性皮疹和龈周分泌物的脓疱进行细菌培养标本在甲沟炎患者中。结果:29例患者中有24例发生丘疹性丘疹反应; 29例中有5例患有甲沟炎/干燥症。在丘疹脓疱症患者中,出现皮疹的时间分为两个不同的组:早期阶段,药物启动后中位数为8天,主要位于面部(n = 17);晚期阶段,药物启动后中位数为约200天,位于主要在树干上(n = 7)。在测试的13位早期患者中有7位以及所有晚期患者的细菌培养均会产生金黄色葡萄球菌(SA)。治疗包括局部类固醇与或不具有局部/全身抗生素。所有患者的皮肤症状在几天内都有明显改善。在29名患者中只有4名需要减少剂量或暂时终止EGFRI。结论:如文献所述,EGFRI诱导的丘疹性脓疱疹可能较早出现,可能是有或没有SA继发感染的炎性过程。乳头丘疹喷发也可能出现在晚期,这是第一次描述,这是一个感染过程,所有患者均为SA(+)。在我们的研究中,SA感染的总发生率> 50%突显了需要进行EGFRI诱导喷发的常规细菌培养。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号